These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 18804742)
21. The influence of statin medications on prostate-specific antigen levels. Hamilton RJ; Goldberg KC; Platz EA; Freedland SJ J Natl Cancer Inst; 2008 Nov; 100(21):1511-8. PubMed ID: 18957682 [TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310 [TBL] [Abstract][Full Text] [Related]
23. Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry. Gitt AK; Juenger C; Jannowitz C; Karmann B; Senges J; Bestehorn K Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):438-44. PubMed ID: 19369876 [TBL] [Abstract][Full Text] [Related]
24. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691 [TBL] [Abstract][Full Text] [Related]
26. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study. Michos ED; Blumenthal RS J Am Coll Cardiol; 2009 Mar; 53(11):931-5. PubMed ID: 19281922 [TBL] [Abstract][Full Text] [Related]
36. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. Willich SN; Englert H; Sonntag F; Völler H; Meyer-Sabellek W; Wegscheider K; Windler E; Katus H; Müller-Nordhorn J Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):180-7. PubMed ID: 19174696 [TBL] [Abstract][Full Text] [Related]
37. The patient at risk: who should we be treating? Leitersdorf E Br J Clin Pract Suppl; 1994 Dec; (77):24-7. PubMed ID: 19496269 [TBL] [Abstract][Full Text] [Related]
38. High marks for below-average cholesterol. For the best protection against clogged arteries and heart disease, average cholesterol no longer makes the grade--lower is better. Harv Heart Lett; 2006 Feb; 16(6):4-5. PubMed ID: 19662696 [No Abstract] [Full Text] [Related]
39. Rosuvastatin in patients with elevated C-reactive protein. Jenny-Avital ER N Engl J Med; 2009 Mar; 360(10):1039; author reply 1041-2. PubMed ID: 19271275 [No Abstract] [Full Text] [Related]
40. Re: The influence of statin medications on prostate-specific antigen levels. Cicero AF; Derosa G; Gaddi AV J Natl Cancer Inst; 2009 Apr; 101(8):610; author reply 610-1. PubMed ID: 19351921 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]